Evidence map›Paper›PMID 39393084›Full record

Trial reportAmerican journal of respiratory and critical care medicine2025

Efficacy and Safety of Admilparant, an LPA

Tamera J Corte, Juergen Behr, Vincent Cottin, Marilyn K Glassberg, Michael Kreuter, Fernando J Martinez, Takashi Ogura, Takafumi Suda, Marlies Wijsenbeek, Elchonon Berkowitz and 5 more

Abstract readClinical Trial, Phase IIRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Multi-omics insights into the mechanisms and prognosis of IPF.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2026
    Review
  8. Lysophosphatidic Acid Receptor 5 (LPAInternational journal of molecular sciences · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Discovery ofJournal of medicinal chemistry · 2026
    Article
  13. Prevalence and Prognostic Impact of Progressive Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Tamera J CorteDepartment of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Juergen BehrDepartment of Medicine V, LMU University Hospital, LMU Munich, Member of the German Center for Lung Research, Munich, Germany.
Vincent CottinNational French Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, University Claude Bernard, Lyon, France.ORCID 0000-0002-5591-0955
Marilyn K GlassbergDepartment of Medicine, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois.
Michael KreuterDepartment of Pneumology, Mainz Center for Pulmonary Medicine, Mainz University Medical Center, Mainz, Germany.
Fernando J MartinezDepartment of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York.
Takashi OguraDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Takafumi SudaDepartment of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Marlies WijsenbeekDepartment of Respiratory Medicine, Center for Interstitial Lung Disease and Sarcoidosis, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Elchonon BerkowitzBristol Myers Squibb, Princeton, New Jersey.
Brandon ElpersBristol Myers Squibb, Princeton, New Jersey.
Sinae KimBristol Myers Squibb, Princeton, New Jersey.
Hideaki WatanabeBristol Myers Squibb, Princeton, New Jersey.
Aryeh FischerBristol Myers Squibb, Princeton, New Jersey.
Toby M MaherDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Southern California, Los Angeles, California; and.ORCID 0000-0001-7192-9149

Funding

Bristol Myers Squibb
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antifibrotic AgentsIdiopathic Pulmonary FibrosisPulmonary FibrosisReceptors, Lysophosphatidic AcidAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeVital CapacityAntifibrotic AgentsReceptors, Lysophosphatidic Acidadmilparant (BMS-986278)antifibroticidiopathic pulmonary fibrosislysophosphatidic acid receptor 1 antagonist

Identifiers

PMID39393084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.